Harnessing Apoptosis in AML

Kapil Saxena, Courtney DiNardo, Naval Daver, Marina Konopleva

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The treatment landscape for AML has grown significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in AML continues to be explored.

Original languageEnglish (US)
Pages (from-to)S61-S64
JournalClinical Lymphoma, Myeloma and Leukemia
Volume20
DOIs
StatePublished - Sep 2020
Externally publishedYes

Keywords

  • AML
  • BCL2
  • MCL1
  • synergy
  • venetoclax

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Harnessing Apoptosis in AML'. Together they form a unique fingerprint.

Cite this